Avacta Group plc, developer of Affimer biotherapeutics and reagents, and Daewoong Pharmaceutical Co. Ltd., a Korean pharmaceutical company, have established a joint venture in South Korea to develop next-gen cell and gene therapies incorporating Affimer proteins to enhance the immune-modulatory effects.    Mesenchymal stem cells (MSCs) are promising agents for the treatment of autoimmune and inflammatory diseases. The joint venture will develop a new class of MSCs that are primed to produce Af...